2021-03-24 13:01:51
In a 2-month randomized clinical trial[1], co-administration of prebiotics and probiotics (“symbiotic”) demonstrated a significant effect at reducing subjective ratings of anxiety and depression, and objective markers of inflammation in 96 patients with coronary artery disease compared to placebo and compared to the administration of either probiotics or prebiotics alone. The probiotic used was 1.9 × 109 colony-forming unit (CFU) of Lactobacillus Rhamnosus G per day with 15g per day of inulin.
In a triple-blind placebo-controlled study[2], researchers looked at the combination of symbiotic supplementation along with low-calorie restriction in 76 post-menopausal, overweight, hormone receptor positive breast cancer patients compared to placebo. Women were separated into two groups to receive either 109 CFU per day of a symbiotic supplement or placebo (n = 38 each group) for eight weeks. Both groups consumed a low-calorie diet program. Compared to the placebo group, patients taking the symbiotic had significantly increased adiponectin and decreased the levels of both inflammatory markers (TNF)-α and hs-CRP. These biomarkers are related to an increased risk of recurrence of breast cancer in this population, therefore symbiotic therapy may be considered as an adjunctive intervention for secondary prevention plan in overweight individuals with a history of breast cancer
References
- Moludi, Jalal, et al. “The effects of co-administration of probiotics and prebiotics on chronic inflammation, and depression symptoms in patients with coronary artery diseases: a randomized clinical trial.” Nutritional Neuroscience (2021): 1-10. https://doi.org/10.1080/1028415X.2021.1889451
- Lahiji, Mahsa Raji, et al. “Effects of symbiotic supplementation on serum adiponectin and inflammation status of overweight and obese breast cancer survivors: a randomized, triple-blind, placebo-controlled trial.” Supportive Care in Cancer (2021): 1-11. https://doi.org/10.1007/s00520-020-05926-8